纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | SREK1 |
Uniprot No | Q9BRV8 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-207aa |
氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSCTIEK ILTDAKTLLE RLREHDAAAE SLVDQSAALH RRVAAMREAG TALPDQYQED ASDMKDMSKY KPHILLSQEN TQIRDLQQEN RELWISLEEH QDALELIMSK YRKQMLQLMV AKKAVDAEPV LKAHQSHSAE IESQIDRICE MGEVMRKAVQ VDDDQFCKIQ EKLAQLELEN KELRELLSIS SESLQARKEN SMDTASQAIK |
预测分子量 | 26 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SREK1重组蛋白的模拟参考文献示例(注:部分内容为假设性概括,实际文献需根据具体研究补充):
---
1. **文献名称**:*Molecular Cloning and Functional Characterization of SREK1 as a Novel Splicing Regulator*
**作者**:Li X. et al.
**摘要**:本研究成功构建了人源SREK1重组蛋白的真核表达系统,通过体外实验证实其通过调控pre-mRNA剪接参与细胞应激反应,并鉴定了其RNA结合结构域的关键功能位点。
2. **文献名称**:*Expression and Purification of Recombinant SREK1 Protein in E. coli for Structural Studies*
**作者**:Zhang Y. et al.
**摘要**:开发了基于大肠杆菌的高效SREK1重组蛋白表达与纯化方案,利用His标签亲和层析获得高纯度蛋白,并通过X射线晶体学初步解析了其N端结构域的构象特征。
3. **文献名称**:*SREK1 Recombinant Protein Interacts with hnRNP A1 to Modulate Alternative Splicing in Cancer Cells*
**作者**:Wang J. et al.
**摘要**:通过Pull-down实验发现重组SREK1蛋白与hnRNP A1存在直接相互作用,并证明该复合物在肺癌细胞中特异性调控靶基因VEGFA的可变剪接,影响肿瘤血管生成。
4. **文献名称**:*Functional Analysis of SREK1 Phosphorylation Sites Using Recombinant Mutant Proteins*
**作者**:Kim S. et al.
**摘要**:构建了SREK1重组蛋白的磷酸化位点突变体,揭示其丝氨酸残基(S58/S126)的磷酸化状态调控核质定位及剪接抑制活性,为相关信号通路研究提供工具。
---
提示:实际文献需通过PubMed等数据库以“SREK1 recombinant protein”或“SREK1 expression”等关键词检索,并筛选涉及重组表达或功能研究的论文。部分研究可能以“CELF2”(SREK1别名)或“RNA splicing”相关主题发表。
**Background of SREK1 Recombinant Protein**
SREK1 (SFRS12/SRp30c), a member of the serine/arginine (SR)-rich protein family, is a key regulator of pre-mRNA splicing, a critical step in eukaryotic gene expression. It interacts with spliceosomal components to modulate alternative splicing events, thereby influencing the diversity of mRNA transcripts and protein isoforms. Structurally, SREK1 contains RNA recognition motifs (RRMs) and a C-terminal RS domain, which facilitate its binding to specific RNA sequences and recruitment of splicing machinery.
Dysregulation of SREK1 has been implicated in diseases such as cancer and neurodegeneration. For instance, altered SREK1 expression disrupts splicing of apoptosis-related genes, promoting tumor survival. In neurodegenerative contexts, aberrant splicing linked to SREK1 dysfunction contributes to pathologies like Alzheimer’s disease.
Recombinant SREK1 protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells*), retains its functional domains and is utilized to study splicing mechanisms *in vitro*. Researchers employ it in pull-down assays, RNA-protein interaction studies, and high-throughput screens to identify splicing modulators. Additionally, it serves as a tool for investigating post-translational modifications (e.g., phosphorylation) that regulate its activity.
The development of SREK1 recombinant protein has advanced therapeutic research, particularly in targeting splicing errors in genetic disorders or cancer. Its role in viral RNA processing also makes it relevant for studying host-pathogen interactions. Overall, SREK1 recombinant protein is a vital resource for dissecting splicing regulation and its implications in health and disease.
*(Word count: 200; remaining space allows for expansion if needed)*
×